169 related articles for article (PubMed ID: 38321024)
1. Transcription factor ATMIN facilitates chemoresistance in nasopharyngeal carcinoma.
Fang XL; Li QJ; Lin JY; Huang CL; Huang SY; Tan XR; He SW; Zhu XH; Li JY; Gong S; Qiao H; Li YQ; Liu N; Ma J; Zhao Y; Tang LL
Cell Death Dis; 2024 Feb; 15(2):112. PubMed ID: 38321024
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
Zhou R; Zhu J; Chen X; Liu Y; Wang Y; Zhang T
Clin Transl Oncol; 2020 Mar; 22(3):429-439. PubMed ID: 31165410
[TBL] [Abstract][Full Text] [Related]
3. Survival benefit of adding docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma with nodal Stage N2-3.
Kawahira M; Yokota T; Hamauchi S; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
Jpn J Clin Oncol; 2017 Aug; 47(8):705-712. PubMed ID: 28431119
[TBL] [Abstract][Full Text] [Related]
4. Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma.
Chen R; Lu Y; Zhang Y; He R; Tang F; Yuan W; Li Y; Zhang X
Medicine (Baltimore); 2021 Oct; 100(42):e27475. PubMed ID: 34678878
[TBL] [Abstract][Full Text] [Related]
5. Short-term outcomes of induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) in locally advanced nasopharyngeal carcinoma.
Takamizawa S; Honma Y; Murakami N; Mori T; Oka H; Yamamoto S; Kashihara T; Ito K; Kubo Y; Ikeda A; Matsumoto F; Omura G; Kobayashi K; Itami J; Kato K; Yoshimoto S
Invest New Drugs; 2021 Apr; 39(2):564-570. PubMed ID: 32940872
[TBL] [Abstract][Full Text] [Related]
6. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.
Kong L; Zhang Y; Hu C; Guo Y; Lu JJ
Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641
[TBL] [Abstract][Full Text] [Related]
7. International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents.
Casanova M; Özyar E; Patte C; Orbach D; Ferrari A; Veyrat-Follet C; Errihani H; Pan J; Zhang L; Shen L; Grzegorzewski KJ; Varan A
Cancer Chemother Pharmacol; 2016 Feb; 77(2):289-98. PubMed ID: 26666649
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine combined with cisplatin vs. taxane, cisplatin, and fluorouracil in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective case-control study.
Huang YM; Qiao SQ; Lu L; Chen WP; Li SL; Qi CH
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7655-7663. PubMed ID: 32744691
[TBL] [Abstract][Full Text] [Related]
9. Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma.
Zhu J; Duan B; Shi H; Li Y; Ai P; Tian J; Chen N
Oral Oncol; 2019 Oct; 97():37-43. PubMed ID: 31421469
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel and cisplatin induction chemotherapy with or without fluorouracil in locoregionally advanced nasopharyngeal carcinoma: A retrospective propensity score matching analysis.
Tao HY; Zhan ZJ; Qiu WZ; Liao K; Yuan YW; Zheng RH
Asia Pac J Clin Oncol; 2022 Apr; 18(2):e111-e118. PubMed ID: 33945215
[TBL] [Abstract][Full Text] [Related]
11. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.
Liu GY; Lv X; Wu YS; Mao MJ; Ye YF; Yu YH; Liang H; Yang J; Ke LR; Qiu WZ; Huang XJ; Li WZ; Guo X; Xiang YQ; Xia WX
Cancer Commun (Lond); 2018 May; 38(1):21. PubMed ID: 29764487
[TBL] [Abstract][Full Text] [Related]
12. Concurrent Chemoradiotherapy with Docetaxel, Cisplatin and 5-Fluorouracil (TPF) in Patients with Nasopharyngeal Carcinoma.
Komatsu M; Arai Y; Yabuki K; Sano D; Shiono O; Sakuma Y; Nishimura G; Takahashi M; Taguchi T; Oridate N
Anticancer Res; 2015 Dec; 35(12):6861-7. PubMed ID: 26637908
[TBL] [Abstract][Full Text] [Related]
13. Long term complications and prognostic factors in locally advanced nasopharyngeal carcinoma treated with docetaxel, cisplatin, 5-fluorouracil induction chemotherapy followed by concurrent chemoradiotherapy: A retrospective cohort study.
Shim HJ; Kim HJ; Hwang JE; Bae WK; Chung IJ; Lee DH; Mi YT; Lee JK; Lim SC; Chung JW; Cho SH
Medicine (Baltimore); 2020 Dec; 99(49):e23173. PubMed ID: 33285692
[TBL] [Abstract][Full Text] [Related]
14. Tumor response to neoadjuvant chemotherapy predicts long-term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: A secondary analysis of a randomized phase 3 clinical trial.
Peng H; Chen L; Li WF; Guo R; Mao YP; Zhang Y; Guo Y; Sun Y; Ma J
Cancer; 2017 May; 123(9):1643-1652. PubMed ID: 28001301
[TBL] [Abstract][Full Text] [Related]
15. In search for optimal induction chemotherapy for advanced nasopharyngeal cancer: Standard dosing of Docetaxel, Platinum, and 5-Fluorouracil (TPF) followed by chemoradiation.
Jun M; Pinto H; Le QT; Quon A; Hara W; Coty J; McMillan A; Lu R; Winters E; Lira R; Colevas AD
PLoS One; 2023; 18(2):e0276651. PubMed ID: 36730145
[TBL] [Abstract][Full Text] [Related]
16. Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study.
Lu Y; Chen D; Liang J; Gao J; Luo Z; Wang R; Liu W; Huang C; Ning X; Liu M; Huang H
BMC Cancer; 2019 Dec; 19(1):1262. PubMed ID: 31888551
[TBL] [Abstract][Full Text] [Related]
17. Prospective, Multicenter, Phase 2 Trial of Induction Chemotherapy Followed by Bio-Chemoradiotherapy for Locally Advanced Recurrent Nasopharyngeal Carcinoma.
Ng WT; Ngan RKC; Kwong DLW; Tung SY; Yuen KT; Kam MKM; Sze HCK; Yiu HHY; Chan LLK; Lung ML; Lee AWM
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):630-638. PubMed ID: 29413277
[TBL] [Abstract][Full Text] [Related]
18. A Retrospective Study to Compare Five Induction Chemotherapy Regimens Prior to Radiotherapy in the Reduction of Regional Lymph Node Size in Patients with Nasopharyngeal Carcinoma.
Chen J; Qi J; Yu B; Peng XH; Wang F; Tan JJ; Chen QQ; Peng XY; Zeng FF; Liu X
Med Sci Monit; 2018 Apr; 24():2562-2568. PubMed ID: 29697098
[TBL] [Abstract][Full Text] [Related]
19. CircIPO7 Promotes Nasopharyngeal Carcinoma Metastasis and Cisplatin Chemoresistance by Facilitating YBX1 Nuclear Localization.
Hong X; Li Q; Li J; Chen K; He Q; Zhao Y; Liang Y; Zhao Y; Qiao H; Liu N; Ma J; Li Y
Clin Cancer Res; 2022 Oct; 28(20):4521-4535. PubMed ID: 35917517
[TBL] [Abstract][Full Text] [Related]
20. Circular RNA CRIM1 functions as a ceRNA to promote nasopharyngeal carcinoma metastasis and docetaxel chemoresistance through upregulating FOXQ1.
Hong X; Liu N; Liang Y; He Q; Yang X; Lei Y; Zhang P; Zhao Y; He S; Wang Y; Li J; Li Q; Ma J; Li Y
Mol Cancer; 2020 Feb; 19(1):33. PubMed ID: 32061262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
